Why MiNK Therapeutics Stock Is Up 11% Monday
MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million.
What’s Going On With Reneo Pharmaceuticals Stock Today?
Reneo and Onkure announced Monday that they have entered into a definitive merger agreement to combine the two companies in an all-stock transaction.
Why Tevogen Bio Holdings Stock Is Moving Higher Today
Tevogen shares are rising Monday after the company secured up to $50 million of financing from an existing investor aimed at supporting continued research and development efforts for Tevogen's TVGN 489.
Why Match Group Stock Is Down 6% Wednesday
Match Group reported earnings on Tuesday after the market close that included GAAP EPS of 44 cents, beating analysts estimates of 41 cents. Match Group also reported sales of $859.658 million, beating analyst estimates of $855.511 million. The company's sales results were up 9.21% from the same period last year.
Cirrus Logic Shares Rise After Q4 Earnings Results
Cirrus Logic reported fourth quarter results for 2024 after the market close on Tuesday that included adjusted EPS of $1.24, which came in above analysts estimates of 64 cents.
Why Hims & Hers Health Stock Is Rising Today
After the market close on Monday, Hims & Hers Health reported strong first-quarter results that included revenue of $278.2 million, representing a 46% increase from $190.8 million in the first quarter of 2023. The number beat analyst estimates of $270.382 million.
Why Clearmind Medicine Stock Is Moving Higher
Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.
Why Mullen Automotive Shares Are Moving Higher Today
Mullen Automotive shares are trading higher Monday after the company entered into an agreement with National Auto Fleet Group to sell electric vehicles nationwide.
Why Are Xeris Biopharma Shares Moving Monday?
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and release a glucagon product that will utilize the company's XeriSol technology and Beta Bionic's pump systems.